Table 5. Metabolites showing a significant treatment effect after Bonferroni correction before and after controlling for baseline metabolite levels.
| Baseline Unadjusted | Controlling for Baseline level |
|---|---|
| PC aa C38:0 | |
| Kynurenine | |
| PC aa C36:1 | |
| PC aa C38:3 | PC aa C38:3 |
| PC aa C38:4 | PC aa C38:4 |
| PC aa C40:4 | PC aa C40:4 |
| PC aa C40:5 | PC aa C40:5 |
| PC aa C40:6 | PC aa C40:6 |
| PC ae C34:0 | |
| PC ae C34:2 | |
| PC ae C36:0 | PC ae C36:0 |
| PC ae C36:3 | |
| PC ae C36:4 | PC ae C36:4 |
| PC ae C36:5 | PC ae C36:5 |
| PC ae C38:3 | |
| PC ae C38:4 | PC ae C38:4 |
| PC ae C38:5 | |
| PC ae C38:6 | |
| Tyr | |
| lysoPC a C20:3 | |
| lysoPC a C24:0 |
The first column shows the 12 metabolites whose change from baseline to end point differed significantly between PH and Control groups after Bonferroni correction for multiple testing (adjusted p < 0.01). The second column shows the 18 metabolites that differed between treatment groups in a multiple regression model controlling for baseline metabolite levels (Bonferroni adjusted p < 0.01). The overall direction of significance and changes remained the same regardless of whether baseline was controlled or not (See S5 and S6).